Navigation Links
Combination therapy shows potent tumor growth inhibition in preclinical studies
Date:11/13/2011

SAN FRANCISCO Combining the investigational agents REGN910 and aflibercept yielded statistically significant improvements in antitumor effects in animal models compared with either agent alone, according to results presented at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, held Nov. 12-16, 2011.

"These preclinical findings suggest that combining REGN910 (SAR307746) and aflibercept in the clinic could be an attractive approach for future clinical research," said Alshad S. Lalani, Ph.D., director of strategic oncology development at Regeneron Pharmaceuticals Inc. in Tarrytown, N.Y. "The rationale is that inhibition of tumor angiogenesis by combining antiangiogenesis treatments could translate into more potent and durable antitumor responses than those observed with single-agent therapy."

In this preclinical mouse study, researchers from Regeneron and BC Cancer Agency in Vancouver, British Columbia, Canada, monitored how REGN910 and aflibercept blocked vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2), which are critical growth factors for tumor angiogenesis, or blood vessel formation.

REGN910 is a fully human monoclonal antibody discovered using Regeneron VelocImmune antibody technology that binds and inhibits Ang2. Aflibercept is a fully human fusion protein that binds all forms of VEGF-A, as well as VEGF-B and placental growth factor. REGN910 and aflibercept are being developed by Regeneron and Sanofi.

In addition, researchers performed tissue analyses to monitor the number of tumor blood vessels, tumor hypoxia (oxygen deprivation), tumor cell death and tumor perfusion.

"When used alone in animal studies, both REGN910 and aflibercept blocked tumor angiogenesis and growth; however, the combination of the two led to increased tumor hypoxia and consequently to the death of a large percentage of the tumor cells," Lalani said. "Consistent with its ability
'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Page: 1 2

Related biology news :

1. Manchesters first step to perfect drug combinations
2. Combination HPV diagnostic test for head and neck cancer outperformed other tests
3. Novel drug combination offers therapeutic promise for hard-to-treat cancers
4. The machinery for recombination is part of the chromosome structure
5. Promising developments in vaccine research, development of a vaginal gel and PrEP lead to calls for a combination of biomedical and non biomedical approaches to HIV prevention policy
6. Unique gene combinations control tropical maize response to day lengths
7. A drug combination extends survival in refractory lung cancer patients
8. Microbubble-delivered combination therapy eradicates prostate cancer in vivo
9. Combination therapy provides hope for cure of dangerous infections of cystic fibrosis patients
10. Killing drug-resistant melanoma requires combination therapy
11. Combination therapy reduced HER2-positive breast cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... (June, 2014) Outstanding basic research, a growing ... dedication to patient care have earned the Herbert ... Medical Center (CUMC) and NewYork-Presbyterian Hospital an $18 ... National Cancer Institute (NCI). The grant renews the ... Comprehensive Cancer Centers in New York City and ...
(Date:8/27/2014)... factors thought to be associated with outcomes after ... age of the patient, mechanism of injury, nerve ... method, operation technique, and repair materials. However, despite ... peripheral nerve injuries, there is no agreement regarding ... the dose-effect relationship of the predictors has not ...
(Date:8/27/2014)... research finds , Gamblers show the same tendencies ... has shown. , Researchers, led by Dr Elliot Ludvig ... tests that found that both human gamblers and pigeons ... low-value rewards. , Published in Biology Letters , ... important role that memories of previous biggest wins and ...
Breaking Biology News(10 mins):Herbert Irving Comprehensive Cancer Center awarded $18 million grant 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 3Herbert Irving Comprehensive Cancer Center awarded $18 million grant 4Gamblers are greedy bird-brains, University of Warwick research finds 2
... the body's motor nerve cells grow along proper paths ... inhibiting spinal-cord neurons from regenerating after injury, researchers at ... the researchers found that a component of myelin ?a ... in adult vertebrates ?chemically blocks the ability of nerve ...
... for the first time that bacteria, in addition to ... sparkling wine known as Cava. They report their findings ... Society for Microbiology. , "Bacteria found in Cava samples ... in terms of aroma, flavor, bubble size and bubble ...
... hanging basket style device is at the heart of a plan ... sex drive of a major pest of fruit ... that very same pest. The device allows growers to selectively ... killing other beneficial insects. , The researchers at Warwick HRI, the ...
Cached Biology News:Researchers find molecule that inhibits regrowth of spinal nerve cells 2Researchers find molecule that inhibits regrowth of spinal nerve cells 3After the yeast is gone bacteria continue to develop flavor of sparkling wine 2Hanging baskets of sex and death help fruit growers 2
(Date:8/27/2014)... -- Lisa Kulik saw fireworks for the first time in ... a groundbreaking retinal implant co-invented by Mark Humayun ... University of Southern California (USC) Eye Institute. ... resident who has retinitis pigmentosa, a degenerative disease ... 2, she became the first person west of the ...
(Date:8/27/2014)... , Aug. 27, 2014 Reportbuyer.com has ... The Graphene Opportunity - A Rational View ... The New Nanotech? A similar amount of ... applications ranging from microelectronics to water treatment, but ... the availability of the Graphene Opportunity Report, authored ...
(Date:8/27/2014)... 2014  ARCH Venture Partners, one of the ... development of seed and early-stage advanced technology companies, ... with more than $400 million in subscriptions. ARCH ... target by more than $150 million. ... and potential of our approach to finding and ...
(Date:8/27/2014)... 2014 After the boom of the ... next beverage craze is going to be the stress ... can use Stress Relief energy pattern which can be ... of a beverage, including minerals, herbs and liquids. Stress ... that power into rapid recovery and helping to adapt ...
Breaking Biology Technology:USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 3USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 4USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 5The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 4
... 28 N30 Pharma (N30), a,biopharmaceutical company focused ... regulate nitric oxide bioavailability,announced today that it has ... N30 will use proceeds from this financing ... expand its discovery and preclinical,research in the area ...
... Be Webcast Live On Company,s Website -, TUSTIN, ... ), a clinical stage biopharmaceutical,company developing monoclonal antibodies for ... that senior management will,present at the BIO Investor Forum ... (6:45 pm EDT). The conference will be held at ...
... ITMN ) announced today that it will release ... at 4:00 p.m. Eastern time.,A live conference call and ... time that same day., To access the live ... To access the,webcast, please log on to the company,s ...
Cached Biology Technology:N30 Pharma Announces Financing, Expansion of Board 2Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008 2InterMune to Release Third Quarter 2008 Financial Results on November 6 2
...
Mouse polyclonal antibody raised against a partial recombinant DDEF2. NCBI Entrez Gene ID = 8853...
Mouse monoclonal antibody raised against a full length recombinant SCGB3A2. NCBI Entrez Gene ID = SCGB3A2...
Mouse monoclonal antibody raised against a partial recombinant QARS. NCBI Entrez Gene ID = QARS...
Biology Products: